Form 4: Beam Therapeutics Director Carole Ho Granted Over 33,000 Stock Options

Beam Therapeutics Inc. Director Carole Ho was granted 33,662 stock options with an exercise price of $17.15, as disclosed in a recent SEC Form 4 filing.

Summary

• Carole Ho, a Director of Beam Therapeutics Inc. (BEAM), was granted 33,662 stock options.
• The transaction date for this grant was June 4, 2025.
• Each stock option has an exercise price of $17.15.
• The options will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the next year's annual meeting of stockholders.
• Vesting is contingent upon Ms. Ho's continued service to the board of directors through the vesting date.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Carole Ho directly beneficially owns 33,662 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice, aligning the director's interests with those of shareholders, and is generally viewed as a neutral to slightly positive event for corporate governance and long-term alignment.

Positives

• The grant of stock options aligns the director's financial interests with those of the company's shareholders, incentivizing long-term performance.
• This is a standard form of compensation for directors, indicating ongoing commitment and engagement from key personnel.

Future Outlook

The stock options are subject to a vesting schedule, which will occur on the earlier of the first anniversary of the grant date or immediately prior to the next year's annual meeting of stockholders, provided the director continues her service to the board.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align interests with long-term company performance.

Comparison to Industry Standards

• Granting equity compensation, such as stock options, to non-employee directors is a widely accepted practice across publicly traded companies, including those in the biotech sector like Beam Therapeutics.
• The vesting schedule tied to continued service is a standard mechanism to ensure ongoing commitment from board members.

Corporate Governance

Related Party Transactions

• Grant of 33,662 stock options to Carole Ho, a Director of Beam Therapeutics Inc., as part of her compensation, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also improved alignment of director's interests with long-term company performance.
• Director (Carole Ho): Receives additional equity compensation, increasing her stake and incentive in the company's success.

Next Steps

• The stock options will vest based on the specified conditions (first anniversary of grant or prior to next annual meeting, subject to continued service).
• Upon vesting, the director will have the right to exercise these options to acquire common stock at the exercise price.

Key Dates

Recommendation

Keywords

Beam Therapeutics, BEAM, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Form 4, Corporate Governance